title: Time to first shock in implantable cardioverter defibrillator (ICD) patients with Chagas cardiomyopathy.
abstract: The time to first ICD shock has been extensively studied in patients with coronary artery disease (CAD). However, there are no published data on ICD shocks in patients with Chagas cardiomyopathy (ChC). The occurrence of the first appropriate ICD shock during the first 6 months of follow-up in 20 patients with ChC (group 1) and 35 CAD patients (group 2) was analyzed retrospectively. All patients had received a third-generation pectoral ICD for ventricular tachycardia or fibrillation (VT/VF). Indications for ICD implantation were refractoriness to drug therapy or noninducibility of VT/VF at EPS in cardiac arrest survivors.
  
  
  RESULTS
  The mean age, left ventricular ejection fraction (LVEF), and sex in groups I and II were 57.4 +/- 7 years versus 64 +/- 9 (P < 0.01), 30.9% +/- 10% versus 32.9% +/- 10% (P = NS), and 10 men versus 31 women (P < 0.005), respectively. Six months after ICD implantation, 85% (17/20) group I patients received appropriate ICD shocks versus 51% (18/35) in group 2, a statistically significant difference (P < 0.02, RR: 1.65, OR: 5.35).
  
  
  CONCLUSIONS
  The incidence of appropriate ICD shocks within the first 6 months postimplantation was significantly higher in ChC patients than in CAD patients. ChC patients were younger and more often women than CAD patients.
authors.affiliation: Sanatorio Mitre, Buenos Aires, Argentina. rfrab@intramed.net.ar
authors.forename: R
authors.initials: R
authors.lastname: Rabinovich
authors.forename: C
authors.initials: C
authors.lastname: Muratore
authors.forename: R
authors.initials: R
authors.lastname: Iglesias
authors.forename: M
authors.initials: M
authors.lastname: Gonzalez
authors.forename: V
authors.initials: V
authors.lastname: Darú
authors.forename: M
authors.initials: M
authors.lastname: Valentino
authors.forename: A S
authors.initials: AS
authors.lastname: Liprandi
authors.forename: R
authors.initials: R
authors.lastname: Luceri
mesh_terms: D000328:Adult; D000368:Aged; D002598:Chagas Cardiomyopathy / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D017147:Defibrillators, Implantable; D004554:Electric Countershock / Q000295:instrumentation*; D005260:Female; D005500:Follow-Up Studies; D006323:Heart Arrest / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006339:Heart Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D013318:Stroke Volume; D015996:Survival Rate; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000209:etiology / Q000503:physiopathology / Q000628:therapy